A very small phase II study of a therapeutic vaccine has indicated some potential in the treatment of glioblastoma multiforme, a malignant brain cancer.
The vaccine, PF-04948568 (CDX-110), made by Celldex, was given to 18 patients in the study, while a control group of 17 patients received standard care for this disease, radiation and chemotherapy in the form of temozolomide.
Results showed that those in the vaccine arm lived an average of 11 months longer than those in the control arm. However, researchers concluded that at most, this trial warranted further investigation in a larger, phase III trial. Additionally, the final enrollment in the study was 35 patients, substantially below the estimated enrollment of 82.
CANCER TYPE(S)
Glioblastoma multiforme
TREATMENT TYPE(S)
Therapeutic vaccine
WHERE WAS THIS STUDY PUBLISHED?
Journal of Clinical Oncology
Source
Clinical Trial NCT00458601
JCO
MSNBC
Accompanying editorial regarding cancer vaccines and glioma
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
